The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome

The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in... Purpose The purpose of the study was to evaluate protein expression of PD-L1 and CD20 as prognostic biomarkers of patient outcome in inflammatory breast cancer (IBC) samples. Methods PD-L1 and CD20 protein expression was measured by immunohistochemistry in 221 pretreatment IBC biopsies. + + PD-L1 was assessed in tumor cells (PD-L1 tumor cells) and tumor stromal infiltrating lymphocytes (PD-L1 TILs); CD20 was scored in tumor-infiltrating B cells. Kaplan–Meier curves and Cox proportional hazard models were used for survival analysis. + + + + Results PD-L1 tumor cells, PD-L1 TILs, and CD20 TILs were found in 8%, 66%, and 62% of IBC, respectively. PD-L1 tumor cells strongly correlated with high TILs, pathological complete response (pCR), CD20 TILs, but marginally with + + breast cancer-specific survival (BCSS, P = 0.057). PD-L1 TILs strongly correlated with high TILs, CD20 TILs, and longer disease-free survival (DFS) in all IBC and in triple-negative (TN) IBC (P < 0.035). IBC and TN IBC patients with + + + + tumors containing both CD20 TILs and PD-L1 TILs (CD20 TILs/PD-L1 TILs) showed longer DFS and improved BCSS + + (P < 0.002) than patients lacking both, or those with either CD20 TILs or PD-L1 TILs alone. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Breast Cancer Research and Treatment Springer Journals

The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome

Loading next page...
 
/lp/springer_journal/the-combined-presence-of-cd20-b-cells-and-pd-l1-tumor-infiltrating-2yjbB6I6qz
Publisher
Springer US
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Oncology
ISSN
0167-6806
eISSN
1573-7217
D.O.I.
10.1007/s10549-018-4834-7
Publisher site
See Article on Publisher Site

Abstract

Purpose The purpose of the study was to evaluate protein expression of PD-L1 and CD20 as prognostic biomarkers of patient outcome in inflammatory breast cancer (IBC) samples. Methods PD-L1 and CD20 protein expression was measured by immunohistochemistry in 221 pretreatment IBC biopsies. + + PD-L1 was assessed in tumor cells (PD-L1 tumor cells) and tumor stromal infiltrating lymphocytes (PD-L1 TILs); CD20 was scored in tumor-infiltrating B cells. Kaplan–Meier curves and Cox proportional hazard models were used for survival analysis. + + + + Results PD-L1 tumor cells, PD-L1 TILs, and CD20 TILs were found in 8%, 66%, and 62% of IBC, respectively. PD-L1 tumor cells strongly correlated with high TILs, pathological complete response (pCR), CD20 TILs, but marginally with + + breast cancer-specific survival (BCSS, P = 0.057). PD-L1 TILs strongly correlated with high TILs, CD20 TILs, and longer disease-free survival (DFS) in all IBC and in triple-negative (TN) IBC (P < 0.035). IBC and TN IBC patients with + + + + tumors containing both CD20 TILs and PD-L1 TILs (CD20 TILs/PD-L1 TILs) showed longer DFS and improved BCSS + + (P < 0.002) than patients lacking both, or those with either CD20 TILs or PD-L1 TILs alone.

Journal

Breast Cancer Research and TreatmentSpringer Journals

Published: Jun 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off